Ipamorelin clears the human body in roughly two hours — here is what its pharmacokinetics, and the one human trial, actually measured.

The short version

Ipamorelin is a small lab-made peptide — a chain of five building blocks — that tells the pituitary gland (a hormone gland at the base of the brain) to release a short burst of growth hormone. Its claim to fame is being clean about it: in animal studies it raised growth hormone without raising the stress hormone cortisol, which sets it apart from older peptides in its class ^[1]. The one human study that measured how the body handles it found it leaves fairly fast, with a terminal half-life (the time for the blood level to fall by half) of about two hours, and the growth-hormone burst it triggers peaks around forty minutes after a dose ^[2]. The only human trial of whether it actually does anything useful — for slow bowel recovery after surgery — did not beat placebo ^[3]. It has never been approved as a medicine anywhere. What people report, including the downsides, is on the effects page.

What the ipamorelin pharmacokinetics establish

Ipamorelin is a synthetic pentapeptide (a five-amino-acid chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor — formally the growth hormone secretagogue receptor 1a, or GHS-R1a (the same receptor the body's natural hunger hormone uses) — on the pituitary gland's somatotrophs (the cells that make growth hormone). Activation triggers a discrete pulse of growth hormone (GH) release ^[1].

The single published human pharmacokinetic study is the foundation a due-diligence reading begins from. In eight healthy male volunteers per dose level, given five 15-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg, the kinetics were linear and dose-proportional: a terminal half-life of approximately 2 hours, plasma clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg. The GH response was a single pulse that peaked at about 0.67 hours — roughly 40 minutes — after dosing ^[2]. Those are the numbers that anchor every honest claim on this site, and they are reproduced on the how long does ipamorelin stay in your system page.

What the pharmacokinetics do not establish is therapeutic benefit. That is a separate question, and the human answer to it so far is negative.

Why a site named for legitimacy leads with the evidence, not the marketing

"Legit" here means one thing: holding ipamorelin's reputation up against the published record and reporting the gap honestly, in either direction. The mechanism is real and well-characterized — the 1998 founding study established ipamorelin as the first highly GH-selective secretagogue, releasing GH as potently as GHRP-6 in swine (ED50 2.3 nmol/kg vs 3.9 nmol/kg) while leaving ACTH and cortisol essentially unmoved even at doses more than 200-fold above its GH threshold ^[1].

But mechanism is not outcome. The only controlled human efficacy trial — a Phase 2 study in 114 bowel-resection patients — missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach significance (p=0.15) ^[3]. Widespread promotion of ipamorelin for anti-aging, fat loss, and muscle gain rests on mechanism and short rodent studies, not on controlled human outcomes. A legitimate reading keeps those two things apart.

The selectivity finding, and where the evidence thins

Ipamorelin's selectivity is its most reproducible result. It releases GH through the ghrelin-receptor (GHS-R1a) pathway, a mechanism distinct from and complementary to growth-hormone-releasing hormone (GHRH) — which is the pharmacological basis for pairing it with GHRH analogs such as CJC-1295 ^[1]. In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day raised the longitudinal bone-growth rate from 42 to 52 micrometers per day in a dose-dependent way, notably without any measurable change in circulating IGF-1 — evidence that part of the skeletal effect is driven locally by the GH pulse rather than by sustained systemic IGF-1 ^[4].

The human evidence, by contrast, is limited and largely negative for the indications tested. There are no completed Phase 3 trials, no approved indication, and no long-term human safety database. The full mechanism and study breakdown is on the Ipamorelin research page; the reported real-world effects and the cited safety cautions are on the effects page.